ARS Pharma reports $275M cash as of Dec 31, 2022; updates corporate presentation

ARS Pharmaceuticals, Inc.

Cash and securities of approximately $275 million as of December 31, 2022.
Updated corporate presentation (Exhibit 99.1) highlights needle-free epinephrine solution for allergic reactions.
No additional financial results, guidance, or operational milestones disclosed in this filing.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.